Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2211) 2211
Publication (205) 205
Newsletter (137) 137
Book Chapter (10) 10
Book Review (10) 10
Newspaper Article (8) 8
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1707) 1707
mucormycosis (1439) 1439
male (1073) 1073
mucormycosis - drug therapy (886) 886
index medicus (788) 788
antifungal agents - therapeutic use (766) 766
female (728) 728
middle aged (673) 673
amphotericin b - therapeutic use (606) 606
adult (595) 595
zygomycosis (537) 537
mucormycosis - diagnosis (505) 505
mucormycosis - microbiology (387) 387
infectious diseases (379) 379
aged (372) 372
mucormycosis - complications (333) 333
diagnosis (313) 313
microbiology (313) 313
health aspects (301) 301
care and treatment (285) 285
amphotericin b (274) 274
immunocompromised host (270) 270
mucormycosis - pathology (261) 261
mucormycosis - etiology (259) 259
aspergillosis (244) 244
risk factors (244) 244
antifungal agents (243) 243
infections (236) 236
fatal outcome (225) 225
treatment outcome (224) 224
adolescent (223) 223
mucormycosis - surgery (218) 218
surgery (216) 216
posaconazole (214) 214
mycology (211) 211
infection (202) 202
child (200) 200
transplantation (199) 199
epidemiology (197) 197
mortality (194) 194
fungal infections (191) 191
therapy (186) 186
amphotericin-b (185) 185
antifungal agents - administration & dosage (185) 185
triazoles - therapeutic use (177) 177
immunology (176) 176
tomography, x-ray computed (174) 174
amphotericin b - administration & dosage (162) 162
diabetes (162) 162
fungi (162) 162
mucormycosis - therapy (162) 162
research (162) 162
rhinocerebral mucormycosis (159) 159
rhizopus (154) 154
mycoses (153) 153
debridement (149) 149
rhizopus - isolation & purification (149) 149
voriconazole (143) 143
fungal-infections (132) 132
lung diseases, fungal - drug therapy (132) 132
pharmacology & pharmacy (132) 132
dermatology (129) 129
animals (126) 126
hematology (126) 126
management (122) 122
mucorales - isolation & purification (122) 122
retrospective studies (122) 122
combined modality therapy (121) 121
medicine & public health (118) 118
case report (117) 117
disease (117) 117
antiparasitic agents (113) 113
case studies (113) 113
zygomycosis - drug therapy (113) 113
leukemia (112) 112
patient (112) 112
pediatrics (109) 109
drug therapy (108) 108
diagnosis, differential (107) 107
aspergillosis - drug therapy (106) 106
young adult (106) 106
drug therapy, combination (102) 102
diabetes mellitus (101) 101
mycoses - drug therapy (100) 100
oncology (98) 98
patients (98) 98
mucormycosis - epidemiology (96) 96
medicine, general & internal (95) 95
child, preschool (94) 94
medical research (94) 94
magnetic resonance imaging (92) 92
mucorales (92) 92
liposomal amphotericin-b (90) 90
biopsy (89) 89
diabetes complications (88) 88
medicine, experimental (85) 85
aspergillus (82) 82
analysis (80) 80
cancer (78) 78
lung diseases, fungal - diagnosis (78) 78
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2183) 2183
Spanish (57) 57
French (47) 47
German (26) 26
Japanese (18) 18
Chinese (6) 6
Russian (4) 4
Dutch (3) 3
Portuguese (3) 3
Czech (2) 2
Danish (2) 2
Hungarian (2) 2
Italian (2) 2
Korean (2) 2
Norwegian (2) 2
Polish (2) 2
Turkish (2) 2
Croatian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Treatment of cerebral mucormycosis with drug therapy alone: A case report
by Elzein, Fatehi and Elzein, Ahmed and Kalam, Kiran and Mohammed, Nazik and Alotaibi, Fadhel Zaben and Khan, Mujtaba and Albadani, Abeer
Medical Mycology Case Reports, ISSN 2211-7539, 03/2019, Volume 23, pp. 4 - 7
We report on an elderly male patient with headache and right-side weakness. Imaging studies revealed multiple space-occupying lesions in the parietal and... 
Antifungal therapy | Liposomal amphotericin B | Cerebral mucormycosis | Posaconazole | Fungal infection
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Delaying Amphotericin B-Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis
by Georgios Chamilos and Russell E. Lewis and Dimitrios P. Kontoyiannis
Clinical Infectious Diseases, ISSN 1058-4838, 8/2008, Volume 47, Issue 4, pp. 503 - 509
Background. Zygomycosis is an emerging opportunistic mycosis among immunocompromised patients with a particularly poor prognosis. Methods. We analyzed the... 
Antifungals | Health outcomes | Delayed diagnosis | Mortality | Hematologic neoplasms | Articles and Commentaries | Aspergillosis | Infections | Fungal infections | Symptoms | Zygomycosis | INFECTIOUS DISEASES | RECEIVING VORICONAZOLE | MICROBIOLOGY | IMMUNOLOGY | MUCORMYCOSIS | FUNGAL-INFECTIONS | CELL TRANSPLANT RECIPIENTS | INVASIVE PULMONARY ASPERGILLOSIS | IMMUNOCOMPROMISED PATIENTS | BACTEREMIA | CARE CANCER CENTER | HALO SIGN | EPIDEMIOLOGY | Multivariate Analysis | Drug Administration Schedule | Hematologic Neoplasms - mortality | Humans | Middle Aged | Zygomycosis - microbiology | Zygomycosis - mortality | Male | Antifungal Agents - therapeutic use | Time Factors | Adolescent | Amphotericin B - administration & dosage | Adult | Female | ROC Curve | Aged | Hematologic Neoplasms - complications | Immunocompromised Host | Amphotericin B - therapeutic use | Antifungal Agents - administration & dosage | Child | Zygomycosis - drug therapy | Mucormycosis | Amphotericin B | Patient outcomes | Dosage and administration | Research | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
by Marty, Francisco M, MD and Ostrosky-Zeichner, Luis, MD and Cornely, Oliver A, Prof and Mullane, Kathleen M, DO and Perfect, John R, MD and Thompson, George R, MD and Alangaden, George J, MD and Brown, Janice M, MD and Fredricks, David N, MD and Heinz, Werner J, MD and Herbrecht, Raoul, MD and Klimko, Nikolai, MD and Klyasova, Galina, Prof and Maertens, Johan A, Prof and Melinkeri, Sameer R, MD and Oren, Ilana, MD and Pappas, Peter G, MD and Ráčil, Zdeněk, MD and Rahav, Galia, MD and Santos, Rodrigo, MD and Schwartz, Stefan, MD and Vehreschild, J Janne, MD and Young, Jo-Anne H, MD and Chetchotisakd, Ploenchan, MD and Jaruratanasirikul, Sutep, MD and Kanj, Souha S, MD and Engelhardt, Marc, MD and Kaufhold, Achim, MD and Ito, Masanori, PhD and Lee, Misun, PhD and Sasse, Carolyn and Maher, Rochelle M, MS and Zeiher, Bernhardt, MD and Vehreschild, Maria J G T, MD and VITAL & FungiScope Mucormycosis In and VITAL and FungiScope Mucormycosis Investigators
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 7, pp. 828 - 837
Summary Background Mucormycosis is an uncommon invasive fungal disease with high mortality and few treatment options. Isavuconazole is a triazole active in... 
Infectious Disease | VORICONAZOLE | MYCOSES STUDY-GROUP | INFECTIOUS DISEASES | INVASIVE ASPERGILLOSIS | POSACONAZOLE | ZYGOMYCOSIS | SALVAGE THERAPY | TRANSPLANT RECIPIENTS | EUROPEAN-ORGANIZATION | LIPOSOMAL AMPHOTERICIN-B | FUNGAL-INFECTIONS | Humans | Middle Aged | Male | Treatment Outcome | Antifungal Agents - therapeutic use | Fungi | Administration, Intravenous | Animals | Aspergillosis - mortality | Adult | Female | Mucormycosis - drug therapy | Aspergillosis - drug therapy | Nitriles - therapeutic use | Pyridines - therapeutic use | Triazoles - therapeutic use | Clinical trials | Mucormycosis | Care and treatment | Analysis | Pneumonia | Disease | Hematology | Mortality | Bioavailability | Health risk assessment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
by Spellberg, Brad and Ibrahim, Ashraf S and Chin-Hong, Peter V and Kontoyiannis, Dimitrios P and Morris, Michele I and Perfect, John R and Fredricks, David and Brass, Eric P
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 3/2012, Volume 67, Issue 3, pp. 715 - 722
Objectives Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron... 
Antifungal | Fungal infections | Combination therapy | Mould infections | mould infections | MORTALITY | INFECTIOUS DISEASES | INFECTIONS | DIABETIC-KETOACIDOSIS | ZYGOMYCOSIS | MICROBIOLOGY | RHIZOPUS | IRON CHELATION | fungal infections | LIPOSOMAL AMPHOTERICIN-B | antifungal | TRANSFERRIN | combination therapy | PHARMACOLOGY & PHARMACY | EXPERIENCE | DEFEROXAMINE THERAPY | Triazoles - administration & dosage | Mucormycosis - mortality | Double-Blind Method | Humans | Middle Aged | Male | Treatment Outcome | Benzoates - administration & dosage | Drug Therapy, Combination - methods | Animals | Survival Analysis | Amphotericin B - administration & dosage | Adult | Female | Aged | Iron Chelating Agents - administration & dosage | Mice | Mucormycosis - drug therapy | Antifungal Agents - administration & dosage | Placebos - administration & dosage | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Posaconazole as Salvage Therapy for Zygomycosis
by R. N. Greenberg and K. Mullane and J.-A. H. van Burik and I. Raad and M. J. Abzug and G. Anstead and R. Herbrecht and A. Langston and K. A. Marr and G. Schiller and M. Schuster and J. R. Wingard and C. E. Gonzalez and S. G. Revankar and G. Corcoran and R. J. Kryscio and R. Hare
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 01/2006, Volume 50, Issue 1, pp. 126 - 133
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
CELL TRANSPLANT RECIPIENTS | IMMUNOCOMPROMISED PATIENTS | CARE CANCER CENTER | B LIPID COMPLEX | RECEIVING VORICONAZOLE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INVASIVE FUNGAL-INFECTIONS | AMPHOTERICIN-B | ITRACONAZOLE | MUCORMYCOSIS | EPIDEMIOLOGY | Antifungal Agents - pharmacology | Triazoles - administration & dosage | Fungi - drug effects | Administration, Oral | Humans | Middle Aged | Zygomycosis - microbiology | Male | Treatment Outcome | Antifungal Agents - therapeutic use | Triazoles - pharmacology | Antifungal Agents - pharmacokinetics | Adolescent | Adult | Female | Triazoles - pharmacokinetics | Aged | Immunocompromised Host | Antifungal Agents - administration & dosage | Child | Zygomycosis - drug therapy | Triazoles - therapeutic use | Clinical Therapeutics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Invasive Mycoses: Strategies for Effective Management
by Kontoyiannis, Dimitrios P., MD, ScD
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 1, pp. S25 - S38
Abstract Effective management of invasive fungal infections (IFIs) depends on early individualized therapy that optimizes efficacy and safety. Considering the... 
Internal Medicine | Therapeutic drug monitoring | Echinocandins | Mucormycosis | Amphotericin B | Triazoles | Hepatotoxicity | ORBITAL-CEREBRAL MUCORMYCOSIS | RECEIVING VORICONAZOLE PROPHYLAXIS | IN-VITRO SUSCEPTIBILITIES | BREAKTHROUGH FUNGAL-INFECTIONS | PREEMPTIVE ANTIFUNGAL THERAPY | CLINICAL-PRACTICE GUIDELINES | CELL TRANSPLANT RECIPIENTS | MEDICINE, GENERAL & INTERNAL | HEALTHY MALE-VOLUNTEERS | INFECTIOUS-DISEASES-SOCIETY | LIPOSOMAL-AMPHOTERICIN-B | Triazoles - administration & dosage | Triazoles - adverse effects | Antifungal Agents - adverse effects | Humans | Middle Aged | Mycoses - microbiology | Male | Alanine Transaminase - blood | Antineoplastic Agents - administration & dosage | Echinocandins - administration & dosage | Liver - drug effects | Antineoplastic Agents - adverse effects | Antifungal Agents - pharmacokinetics | Mycoses - metabolism | Adult | Female | Mucormycosis - surgery | Mucormycosis - drug therapy | Alkaline Phosphatase - blood | Myelodysplastic Syndromes - drug therapy | Aspergillosis - drug therapy | Flucytosine - administration & dosage | Liver - metabolism | Risk Factors | Leukemia - drug therapy | Mycoses - surgery | Pneumonia - microbiology | Biomarkers - blood | Bilirubin - blood | Flucytosine - adverse effects | Echinocandins - adverse effects | Pneumonia - drug therapy | Aspartate Aminotransferases - blood | Liver Function Tests - standards | Opportunistic Infections - drug therapy | Mycoses - drug therapy | Immunocompromised Host | Drug Monitoring | Antifungal Agents - administration & dosage | Care and treatment | Mycoses | Diagnosis | Research | Health aspects | Risk factors | Drugs | flucytosine | Pharmacodynamics | Risk groups | Mortality | Antifungal agents | Molds | triazoles | Epidemiology | Radicals | Infection | Lipophilic | hepatotoxicity | Voriconazole | Pharmacokinetics | Posaconazole | Itraconazole
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Changes in the epidemiological landscape of invasive mould infections and disease
by Lass-Flörl, Cornelia and Cuenca-Estrella, Manuel
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 03/2017, Volume 72, Issue suppl_1, pp. i5 - i11
Although a wide variety of pathogens are associated with invasive mould diseases, Aspergillus spp. have historically been one of the most common causative... 
INFECTIOUS DISEASES | RISK-FACTORS | ANTIFUNGAL SUSCEPTIBILITY PROFILE | MICROBIOLOGY | ACUTE MYELOID-LEUKEMIA | AMPHOTERICIN-B | FUNGAL-INFECTIONS | CELL TRANSPLANT RECIPIENTS | INTENSIVE-CARE-UNIT | JOINT CLINICAL GUIDELINES | PHARMACOLOGY & PHARMACY | CYSTIC-FIBROSIS | IN-VITRO ACTIVITY | Aspergillus fumigatus - drug effects | Mucormycosis - epidemiology | Fusariosis - epidemiology | Humans | Scedosporium - drug effects | Drug Resistance, Fungal - physiology | Mucorales - drug effects | Fusarium - drug effects | Aspergillosis - epidemiology | Antifungal Agents - therapeutic use | Invasive Fungal Infections - drug therapy | Mucormycosis - microbiology | Aspergillosis - microbiology | Fusariosis - drug therapy | Immunocompromised Host | Mucormycosis - drug therapy | Invasive Fungal Infections - microbiology | Aspergillosis - drug therapy | Fusariosis - microbiology | Invasive Fungal Infections - immunology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Combination Therapy for Mucormycosis: Why, What, and How?
by Brad Spellberg and Ashraf Ibrahim and Emmanuel Roilides and Russel E. Lewis and Olivier Lortholary and George Petrikkos and Dimitrios P. Kontoyiannis and Thomas J. Walsh
Clinical Infectious Diseases, ISSN 1058-4838, 1/2012, Volume 54, Issue suppl_1, pp. S73 - S78
The high mortality rate of mucormycosis with currently available monotherapy, particularly in hematology patients, has stimulated interest in studying novel... 
Antifungals | Mucormycosis | Animal models | Mucorales | Polyenes | Lipids | Mice | Infections | Dosage | Zygomycosis | RHIZOPUS-ORYZAE | INFECTIOUS DISEASES | LIPID COMPLEX | MICROBIOLOGY | DISSEMINATED ZYGOMYCOSIS | NEUTROPENIC PATIENTS | IMMUNOLOGY | FILAMENTOUS FUNGI | LIPOSOMAL AMPHOTERICIN-B | CELL TRANSPLANT RECIPIENTS | IRON CHELATOR | INVASIVE FUNGAL-INFECTION | CRYPTOCOCCAL MENINGITIS | Triazoles - administration & dosage | Benzoates - therapeutic use | Humans | Treatment Outcome | Clinical Trials as Topic | Lipids - administration & dosage | Lipids - therapeutic use | Antifungal Agents - therapeutic use | Benzoates - administration & dosage | Echinocandins - administration & dosage | Polyenes - administration & dosage | Animals | Polyenes - therapeutic use | Mucormycosis - microbiology | Echinocandins - therapeutic use | Drug Therapy, Combination | Mucormycosis - drug therapy | Antifungal Agents - administration & dosage | Triazoles - therapeutic use | Index Medicus | Supplement
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases
by van Burik, Jo-Anne H and Hare, Roberta S and Solomon, Howard F and Corrado, Michael L and Kontoyiannis, Dimitrios P
Clinical Infectious Diseases, ISSN 1058-4838, 4/2006, Volume 42, Issue 7, pp. e61 - e65
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study... 
INFECTIOUS DISEASES | CARE CANCER CENTER | MICROBIOLOGY | ANTIFUNGAL THERAPY | IMMUNOLOGY | MUCORMYCOSIS | BIOAVAILABILITY | FUNGAL-INFECTIONS | Humans | Middle Aged | Salvage Therapy | Male | Antifungal Agents - therapeutic use | Adolescent | Aged, 80 and over | Adult | Female | Aged | Retrospective Studies | Child | Zygomycosis - drug therapy | Triazoles - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text 2016 guidelines for the use of antifungal agents in patients with invasive fungal diseases in Taiwan
by Kung, Hsiang-Chi and Huang, Po-Yen and Chen, Yee-Chun and Chen, Wei-Ting and Ko, Bor-Sheng and Chang, Shan-Chwen and Chuang, Yin-Ching and Infect Dis Soc Taiwan and Infectious Diseases Society of Taiwan and Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education and CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines and Medical Foundation in Memory of Dr. Deh-Lin Cheng
Journal of Microbiology, Immunology and Infection, ISSN 1684-1182, 02/2018, Volume 51, Issue 1, pp. 1 - 17
The Infectious Diseases Society of Taiwan, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases... 
Antifungal therapy | Mucormycosis | Candidiasis | Definitive therapy | Aspergillosis | Cryptococcosis | DIAGNOSIS | INFECTIOUS DISEASES | RISK-FACTORS | MANAGEMENT | MICROBIOLOGY | TRANSPLANT RECIPIENTS | IMMUNOLOGY | MEDICAL-CENTER | CHANGING EPIDEMIOLOGY | ACUTE-LEUKEMIA | CANDIDA-ALBICANS | BLOOD-STREAM INFECTIONS | Guidelines as Topic | Cryptococcosis - microbiology | Cryptococcus - pathogenicity | Food-Drug Interactions | Humans | Cryptococcosis - drug therapy | Candidiasis - microbiology | Antifungal Agents - therapeutic use | Aspergillus - drug effects | Drug Interactions | Candida - pathogenicity | Candidiasis - drug therapy | Invasive Fungal Infections - drug therapy | Mucormycosis - microbiology | Aspergillosis - microbiology | Mycoses - drug therapy | Taiwan | Aspergillus - pathogenicity | Candida - drug effects | Mucormycosis - drug therapy | Cryptococcus - drug effects | Invasive Fungal Infections - microbiology | Antifungal Agents - standards | Aspergillosis - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Combination Polyene-Caspofungin Treatment of Rhino-Orbital-Cerebral Mucormycosis
by Caitlin Reed and Richard Bryant and Ashraf S. Ibrahim and John Edwards and Scott G. Filler and Robert Goldberg and Brad Spellberg
Clinical Infectious Diseases, ISSN 1058-4838, 8/2008, Volume 47, Issue 3, pp. 364 - 371
Background. It has been axiomatic that echinocandins (e. g., caspofungin) are ineffective against mucormycosis. However, on the basis of preclinical data, we... 
Antifungals | Mucormycosis | Health outcomes | Diabetes complications | Polyenes | Diabetes mellitus | Articles and Commentaries | Lipids | Diabetes | Fungal infections | Lost to follow up | FUNGAL-INFECTION | L-743,872 | INFECTIOUS DISEASES | MICROBIOLOGY | DISSEMINATED ZYGOMYCOSIS | RHIZOPUS | AMPHOTERICIN-B | IMMUNOLOGY | LY303366 | ASPERGILLUS | SYNTHASE | IN-VITRO | EPIDEMIOLOGY | Humans | Middle Aged | Kaplan-Meier Estimate | Child, Preschool | Male | Treatment Outcome | Orbital Diseases - microbiology | Rhinitis - drug therapy | Antifungal Agents - therapeutic use | Rhinitis - microbiology | Adolescent | Aged, 80 and over | Echinocandins - therapeutic use | Adult | Female | Aged | Orbital Diseases - drug therapy | Retrospective Studies | Amphotericin B - therapeutic use | Drug Therapy, Combination | Mucormycosis - drug therapy | Child | Lipopeptides | Cohort Studies | Care and treatment | Caspofungin | Dosage and administration | Research | Drug therapy, Combination
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration
by Michael J. Dolton and John E. Ray and Sharon C.-A. Chen and Kingsley Ng and Lisa Pont and Andrew J. McLachlan
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2012, Volume 56, Issue 11, pp. 5503 - 5510
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
CELL TRANSPLANT RECIPIENTS | ORAL POSACONAZOLE | PROPHYLAXIS | ASPERGILLOSIS | PLASMA | PHARMACOKINETICS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INVASIVE FUNGAL-INFECTIONS | HEALTHY-VOLUNTEERS | ANTIFUNGAL | MUCORMYCOSIS | Triazoles - blood | Humans | Middle Aged | Mycoses - microbiology | Male | Dose-Response Relationship, Drug | Antifungal Agents - pharmacokinetics | Aged, 80 and over | Adult | Female | Triazoles - pharmacokinetics | Mycoses - blood | Retrospective Studies | Rifampin - administration & dosage | Drug Therapy, Combination | Fungi - growth & development | Antifungal Agents - pharmacology | Mycoses - prevention & control | Fungi - drug effects | Logistic Models | Metoclopramide - administration & dosage | Phenytoin - administration & dosage | Triazoles - pharmacology | Adolescent | Mycoses - drug therapy | Aged | Ranitidine - administration & dosage | Australia | Drug Monitoring | Antifungal Agents - blood | Pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights